News Daily News Intracranial Hemorrhage Outside of A-fib: Different NOACs, Different Risks Todd Neale August 13, 2018
News Daily News Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval Todd Neale May 04, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ISC 2018 More Evidence Rivaroxaban May Carry Higher Bleeding Risk Than Other NOACs Todd Neale January 27, 2018